卡普托普利的心脏保护作用:从基本到应用研究
Marko Stoiljkovic1, Vladimir Jakovljevic2,3,4, Jovan Milosavljevic2
1General Hospital "Sveti Luka", 11300 Smederevo, Serbia.
International journal of molecular sciences
|August 14, 2025
概括
卡普托普里尔是一种血管激素转化酶 (ACE) 抑制剂,除了血压控制之外,还提供心脏保护. 它的抗氧化和抗炎作用是其心血管益处的关键,表明更广泛的治疗潜力.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
背景情况:
- 卡普托普利是已知的血管酶转化酶 (ACE) 抑制剂,用于高血压和心力衰竭.
- 它的心脏保护作用归因于血液动力学变化,最近,抗氧化,抗炎和免疫调节作用.
- 新兴研究表明,卡普托普里尔可能具有超出其既定指示的治疗应用.
研究的目的:
- 审查卡普托普里尔在心血管疾病中的保护作用背后的多方面的机制.
- 将基础科学发现与临床应用联系起来,特别是在缺血性再输伤害,高血压和心力衰竭方面.
- 突出卡普托普利在调节与心血管疾病相关的氧化和炎症途径方面的潜力.
主要方法:
- 关于卡普托普利的生物化学和临床研究的综合文献综述.
- 分析调查卡普托普利的抗氧化,抗炎和免疫调节性质的研究.
- 检查卡普托普利在特定心血管疾病中的作用,如缺血性转流损伤,高血压和心力衰竭.
主要成果:
- 卡普托普利显示出显著的抗氧化,抗炎和免疫调节作用,有助于其心脏保护.
- 这些非血动力学机制在诸如缺血再输损伤,高血压和心力衰竭等疾病中至关重要.
- 证据支持卡普托普利在调节心血管医学中关键的氧化和炎症途径方面的有效性.
结论:
- 卡普托普利的保护机制超出了ACE抑制的范围,涉及显著的抗氧化和抗炎作用.
- 这些特性使卡普托普里尔成为治疗心血管疾病的有价值治疗剂.
- 需要进一步的研究来阐明分子点,并优化卡普托普利在心血管和其他潜在疾病中的临床使用.
更多相关视频
09:38Simultaneous Isolation of High Quality Cardiomyocytes, Endothelial Cells, and Fibroblasts from an Adult Rat Heart
Published on: May 19, 2017
13.5K
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
3.6K
相关概念视频
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
881
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
881
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
508
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
508
01:29Cardiomyopathy V: Interprofessional Care
33
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
33
01:30Cardiomyopathy II: Dilated Cardiomyopathy
22
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
22
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
77
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
77
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23